Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jul 12 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-0.03 Insider Own0.43% Shs Outstand136.32M Perf Week8.02%
Market Cap3.75B Forward P/E8.53 EPS next Y3.22 Insider Trans3.70% Shs Float135.73M Perf Month-2.66%
Income-3.90M PEG- EPS next Q0.50 Inst Own96.32% Short Float3.88% Perf Quarter-12.15%
Sales4.56B P/S0.82 EPS this Y0.45% Inst Trans-5.06% Short Ratio3.39 Perf Half Y-17.58%
Book/sh34.39 P/B0.80 EPS next Y24.35% ROA0.01% Short Interest5.26M Perf Year-16.93%
Cash/sh4.83 P/C5.69 EPS next 5Y10.00% ROE0.01% 52W Range24.82 - 40.28 Perf YTD-14.61%
Dividend Est.1.10 (4.00%) P/FCF13.33 EPS past 5Y- ROI-0.05% 52W High-31.78% Beta0.52
Dividend TTM1.10 (4.00%) Quick Ratio1.08 Sales past 5Y0.02% Gross Margin35.64% 52W Low10.74% ATR (14)0.76
Dividend Ex-DateMay 31, 2024 Current Ratio1.81 EPS Y/Y TTM97.23% Oper. Margin5.59% RSI (14)55.24 Volatility2.85% 2.78%
Employees9140 Debt/Eq0.91 Sales Y/Y TTM-0.04% Profit Margin-0.09% Recom1.17 Target Price39.40
Option/ShortYes / Yes LT Debt/Eq0.81 EPS Q/Q467.90% Payout- Rel Volume0.80 Prev Close27.84
Sales Surprise-1.01% EPS Surprise23.46% Sales Q/Q-8.38% EarningsMay 07 BMO Avg Volume1.55M Price27.48
SMA204.71% SMA50-2.47% SMA200-8.81% Trades Volume1,238,314 Change-1.29%
Date Action Analyst Rating Change Price Target Change
Nov-17-23Initiated Piper Sandler Overweight $37
Mar-07-23Initiated Canaccord Genuity Buy $49
Sep-14-22Upgrade Argus Hold → Buy $46
Sep-06-22Upgrade Wells Fargo Equal Weight → Overweight $48 → $54
Oct-14-21Upgrade Raymond James Mkt Perform → Outperform $59
Sep-30-21Upgrade Jefferies Hold → Buy $45 → $63
Apr-07-21Resumed RBC Capital Mkts Sector Perform $51
Jan-06-21Downgrade RBC Capital Mkts Outperform → Sector Perform $59 → $49
Apr-17-20Downgrade Argus Buy → Hold
Mar-24-20Upgrade JP Morgan Neutral → Overweight $57
Jul-10-24 08:00AM
Jun-06-24 11:31AM
May-30-24 11:28AM
May-28-24 08:03AM
May-13-24 11:53AM
10:11AM Loading…
May-07-24 04:31PM
06:28AM Loading…
May-06-24 09:16AM
May-01-24 09:42AM
Apr-30-24 10:59AM
Apr-25-24 10:41AM
Apr-23-24 08:09AM
Apr-15-24 08:15AM
Apr-11-24 09:03AM
Apr-09-24 12:30PM
Apr-04-24 04:37PM
Mar-28-24 11:30AM
Mar-18-24 10:00AM
Mar-05-24 10:48AM
Mar-04-24 11:23AM
08:00AM Loading…
Mar-03-24 10:32AM
Feb-29-24 04:21PM
Feb-28-24 06:13AM
Feb-27-24 12:32PM
Feb-26-24 04:30PM
Feb-20-24 01:32PM
Feb-13-24 08:16AM
Dec-07-23 11:31AM
Nov-29-23 08:54AM
Nov-28-23 01:04PM
Nov-16-23 05:16AM
Nov-15-23 05:03AM
Nov-10-23 09:16AM
Nov-08-23 02:38PM
Nov-07-23 02:16PM
Nov-02-23 01:39PM
Oct-31-23 11:27AM
Oct-30-23 04:35PM
Oct-24-23 09:54AM
Sep-13-23 07:14PM
Sep-11-23 04:05PM
Sep-07-23 11:30AM
Sep-01-23 09:10AM
Aug-24-23 09:41AM
Aug-08-23 11:54AM
Aug-07-23 12:09PM
Aug-02-23 10:19AM
Jul-25-23 09:31AM
Jul-21-23 08:50AM
Jul-14-23 11:01AM
Jul-13-23 05:40PM
Jul-12-23 09:40AM
Jul-05-23 09:40AM
Jun-30-23 09:14AM
Jun-15-23 09:40AM
Jun-14-23 09:55AM
Jun-13-23 12:49PM
Perrigo Co. Plc engages in the provision of self-care products and over the counter health and wellness solutions. It enhances individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. It operates through the Consumer Self-Care Americas and Consumer Self-Care International segments. The Consumer Self-Care Americas segment offers OTC solutions, infant formula, oral care, and contract manufacturing in the U.S, Mexico, and Canada. The Consumer Self-Care International segment includes the self-care business branded in Europe, Australia, the United Kingdom, and parts of Europe and Asia. The company was founded by Luther Perrigo in 1887 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lockwood-Taylor PatrickCEOJul 10 '24Option Exercise27.1628,326769,33448,826Jul 11 12:34 PM
Ives AlisonEVP & Chief Scientific OfficerJul 08 '24Option Exercise25.7292023,66218,930Jul 10 09:51 AM
Bezerra Eduardo GuaritaEVP & Chief Financial OfficerJun 07 '24Option Exercise26.944,532122,09216,563Jun 11 01:44 PM
Andersen SvendEVP & President CHCIMay 28 '24Buy27.901,00027,900101,853May 31 05:04 PM
ASHFORD ORLANDO DDirectorMay 15 '24Option Exercise30.2210,955331,06020,992May 16 07:27 PM
Doyle Katherine C.DirectorMay 15 '24Option Exercise30.228,764264,84819,170May 16 07:27 PM
Mann Erica LDirectorMay 15 '24Option Exercise30.228,764264,84821,665May 16 07:26 PM
KINDLER JEFFREY BDirectorMay 15 '24Option Exercise30.228,764264,84827,214May 16 07:26 PM
O'Connor DonalDirectorMay 15 '24Option Exercise30.228,764264,84829,694May 16 07:28 PM
Parker Geoffrey M.DirectorMay 15 '24Option Exercise30.228,764264,84824,469May 16 07:28 PM
Manzone AlbertDirectorMay 15 '24Option Exercise30.228,764264,84811,612May 16 07:26 PM
Karaboutis AdrianaDirectorMay 15 '24Option Exercise30.228,764264,84826,686May 16 07:26 PM
Alford Bradley ADirectorMay 15 '24Option Exercise30.228,764264,84840,217May 16 07:27 PM
Andersen SvendEVP & President CHCIMar 07 '24Option Exercise29.695,468162,345100,853Mar 08 07:18 PM
Janish Ronald CraigEVP, Gbl Ops & SC & CTOMar 07 '24Option Exercise29.692,94287,34834,439Mar 08 09:18 PM
Quinn GrainneEVP, Chief Medical OfficerMar 07 '24Option Exercise29.692,24966,77322,248Mar 08 09:57 PM
Willis RobertEVP & CHROMar 07 '24Option Exercise29.692,16364,21932,595Mar 08 09:34 PM
Ives AlisonEVP & Chief Scientific OfficerMar 07 '24Option Exercise29.691,74651,83918,536Mar 08 07:36 PM
Bezerra Eduardo GuaritaEVP & Chief Financial OfficerMar 06 '24Option Exercise28.094,870136,79813,298Mar 08 07:51 PM
Andersen SvendEVP & President CHCIMar 06 '24Option Exercise28.093,788106,40595,385Mar 08 07:18 PM
HANSON KYLEEVP & General CounselMar 06 '24Option Exercise28.093,51898,82112,284Mar 08 08:52 PM
Janish Ronald CraigEVP, Gbl Ops & SC & CTOMar 06 '24Option Exercise28.092,30064,60732,190Mar 08 09:18 PM
Ives AlisonEVP & Chief Scientific OfficerMar 06 '24Option Exercise28.092,03057,02317,402Mar 08 07:36 PM
Farrington ThomasEVP and CIOMar 06 '24Option Exercise28.091,88152,83711,389Mar 08 08:17 PM
Quinn GrainneEVP, Chief Medical OfficerMar 06 '24Option Exercise28.091,75949,41020,914Mar 08 09:57 PM
Willis RobertEVP & CHROMar 06 '24Option Exercise28.091,75949,41031,347Mar 08 09:34 PM
Andersen SvendEVP & President CHCIMar 05 '24Option Exercise27.263,41192,98472,152Mar 07 08:31 PM
Janish Ronald CraigEVP, Gbl Ops & SC & CTOMar 05 '24Option Exercise27.262,07156,45522,262Mar 07 09:28 PM
Ives AlisonEVP & Chief Scientific OfficerMar 05 '24Option Exercise27.261,69846,28714,144Mar 07 09:58 PM
Farrington ThomasEVP and CIOMar 05 '24Option Exercise27.261,69346,1514,516Mar 07 08:49 PM
Quinn GrainneEVP, Chief Medical OfficerMar 05 '24Option Exercise27.261,58343,15315,646Mar 07 09:00 PM
Willis RobertEVP & CHROMar 05 '24Option Exercise27.261,27934,86626,755Mar 07 09:10 PM
Ives AlisonEVP & Chief Scientific OfficerMar 05 '24Buy27.262,49067,87716,122Mar 07 09:58 PM
Willis RobertEVP & CHROMar 01 '24Buy26.303719,75725,476Mar 01 02:31 PM
Lockwood-Taylor PatrickCEOFeb 29 '24Buy26.549,500252,16820,500Feb 29 01:39 PM
Willis RobertEVP & CHROFeb 29 '24Buy25.876,000155,22025,105Mar 01 02:31 PM
Ives AlisonEVP & Chief Scientific OfficerFeb 29 '24Buy26.441,54540,85012,446Mar 07 09:54 PM
Willis RobertEVP & CHRONov 24 '23Buy31.015,550172,10619,105Nov 27 07:12 PM
Ives AlisonEVP & Chief Scientific OfficerNov 16 '23Buy29.342,04059,85410,380Nov 17 06:03 AM
Lockwood-Taylor PatrickCEONov 14 '23Buy28.9911,000318,86811,000Nov 14 07:12 PM
Bezerra Eduardo GuaritaEVP & Chief Financial OfficerNov 14 '23Buy29.185,000145,8828,428Nov 15 12:14 PM
Ives AlisonEVP & Chief Scientific OfficerOct 06 '23Option Exercise30.4673822,4799,078Oct 10 08:23 AM
Manzone AlbertDirectorAug 15 '23Option Exercise38.885,478212,9855,478Aug 17 12:48 PM